Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($1.15), in-line with the analyst estimate of ($1.15). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.